GMP Stock Portfolio Up 30% Since April
Summary
- CORT, and RCKT hit targets near 100% to end the year.
- Bitcoin (300%) and commodity calls not included.
- Subscribe now for the 2021 portfolio.
2020 Performance
My Marketplace subscriber service Global Markets Playbook has provided overall portfolio gains of around 30% since it began in April 2020.
Recent winners were seen in Corcept Pharma (CORT) (+118.7%) and Rocket Pharma (RCKT) (+90%).
Closed out positions include:
Peloton (PTON) (+67%), Hecla Mining (HL) (+150%), Joyy Inc (YY) (+80%), JD.COM (+45%), and IIVI (IIVI) (+45%.
I also made some short-term calls on the indices and commodities that are not included. This included Bitcoin (BTC-USD) at $8-9k in the summer, which is now pressing a 300% gain at $23k.
2020 review and 2021 outlook
The GMP portfolio started in April at the height of the pandemic and the mistake I made in 2020 was expecting a shorter lifespan of the virus. This led me to doubt the stock rally and I stayed out of the tech names.
In reality, the gains I have made were in undervalued names and I picked them because I saw a catalyst and clear valuation targets.
The tech rally is now rising on fantasy valuations and this is not a long-term strategy for the long-term. I am also able to apply my experience of commodities to my calls and that was how I created the 150% return in Hecla Mining.
I am about to release my 2021 portfolio before the year-end and this would be an ideal time for investors to get involved if they are cautious about the current valuations.
Subscribe today with a free 14-day trial.
Wishing you a great Christmas and a Happier New Year.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.